FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904167445> ?p ?o ?g. }

• W2904167445 endingPage "1165" @default.
• W2904167445 startingPage "1157" @default.
• W2904167445 abstract "Contrast-enhanced magnetic resonance imaging (CE-MRI) of the breast is highly sensitive for breast cancer detection. Multichannel coils and 3T scanners can increase signal, spatial, and temporal resolution. In addition, the T1 -reduction effect of a gadolinium-based contrast agent (GBCA) is higher at 3T. Thus, it might be possible to reduce the dose of GBCA at 3T without losing diagnostic information.To compare a three-quarter (0.075 mmol/kg) dose of the high-relaxivity GBCA gadobenate dimeglumine, with a 1.5-fold higher than on-label dose (0.15 mmol/kg) of gadoterate meglumine for breast lesion detection and characterization at 3T CE-MRI.Prospective, randomized, intraindividual comparative study.Eligible were patients with imaging abnormalities (BI-RADS 0, 4, 5) on conventional imaging. Each patient underwent two examinations, 24-72 hours apart, one with 0.075 mmol/kg gadobenate and the other with 0.15 mmol/kg gadoterate administered in a randomized order. In all, 109 patients were prospectively recruited.3T MRI with a standard breast protocol (dynamic-CE, T2 w-TSE, STIR-T2 w, DWI).Histopathology was the standard of reference. Three blinded, off-site breast radiologists evaluated the examinations using the BI-RADS lexicon.Lesion detection, sensitivity, specificity, and diagnostic accuracy were calculated per-lesion and per-region, and compared by univariate and multivariate analysis (Generalized Estimating Equations, GEE).Five patients were excluded, leaving 104 women with 142 histologically verified breast lesions (109 malignant, 33 benign) available for evaluation. Lesion detection with gadobenate (84.5-88.7%) was not inferior to gadoterate (84.5-90.8%) (P ≥ 0.165). At per-region analysis, gadobenate demonstrated higher specificity (96.4-98.7% vs. 92.6-97.3%, P ≤ 0.007) and accuracy (96.3-97.8% vs. 93.6-96.1%, P ≤ 0.001) compared with gadoterate. Multivariate analysis demonstrated superior, reader-independent diagnostic accuracy with gadobenate (odds ratio = 1.7, P < 0.001 using GEE).A 0.075 mmol/kg dose of the high-relaxivity contrast agent gadobenate was not inferior to a 0.15 mmol/kg dose of gadoterate for breast lesion detection. Gadobenate allowed increased specificity and accuracy.1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:1157-1165." @default.
• W2904167445 created "2018-12-22" @default.
• W2904167445 creator A5000944221 @default.
• W2904167445 creator A5012168930 @default.
• W2904167445 creator A5013701975 @default.
• W2904167445 creator A5015016922 @default.
• W2904167445 creator A5015268976 @default.
• W2904167445 creator A5033944352 @default.
• W2904167445 creator A5076214794 @default.
• W2904167445 creator A5082840545 @default.
• W2904167445 date "2018-12-15" @default.
• W2904167445 modified "2023-10-16" @default.
• W2904167445 title "Breast lesion detection and characterization with contrast‐enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T" @default.
• W2904167445 cites W1966956500 @default.
• W2904167445 cites W1977327125 @default.
• W2904167445 cites W2012636568 @default.
• W2904167445 cites W2025713601 @default.
• W2904167445 cites W2066095128 @default.
• W2904167445 cites W2077398787 @default.
• W2904167445 cites W2084893557 @default.
• W2904167445 cites W2100759694 @default.
• W2904167445 cites W2101585888 @default.
• W2904167445 cites W2104004877 @default.
• W2904167445 cites W2106039119 @default.
• W2904167445 cites W2109909368 @default.
• W2904167445 cites W2118961597 @default.
• W2904167445 cites W2125470714 @default.
• W2904167445 cites W2134026526 @default.
• W2904167445 cites W2152415663 @default.
• W2904167445 cites W2157600930 @default.
• W2904167445 cites W2160374037 @default.
• W2904167445 cites W2160994099 @default.
• W2904167445 cites W2165872440 @default.
• W2904167445 cites W2312938814 @default.
• W2904167445 cites W2320879921 @default.
• W2904167445 cites W2460098471 @default.
• W2904167445 cites W2460505725 @default.
• W2904167445 cites W2506601463 @default.
• W2904167445 cites W2537015736 @default.
• W2904167445 cites W2626613451 @default.
• W2904167445 cites W2735605977 @default.
• W2904167445 cites W2768286156 @default.
• W2904167445 cites W2792581475 @default.
• W2904167445 doi "https://doi.org/10.1002/jmri.26335" @default.
• W2904167445 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6620600" @default.
• W2904167445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30552829" @default.
• W2904167445 hasPublicationYear "2018" @default.
• W2904167445 type Work @default.
• W2904167445 sameAs 2904167445 @default.
• W2904167445 citedByCount "10" @default.
• W2904167445 countsByYear W29041674452019 @default.
• W2904167445 countsByYear W29041674452020 @default.
• W2904167445 countsByYear W29041674452021 @default.
• W2904167445 countsByYear W29041674452023 @default.
• W2904167445 crossrefType "journal-article" @default.
• W2904167445 hasAuthorship W2904167445A5000944221 @default.
• W2904167445 hasAuthorship W2904167445A5012168930 @default.
• W2904167445 hasAuthorship W2904167445A5013701975 @default.
• W2904167445 hasAuthorship W2904167445A5015016922 @default.
• W2904167445 hasAuthorship W2904167445A5015268976 @default.
• W2904167445 hasAuthorship W2904167445A5033944352 @default.
• W2904167445 hasAuthorship W2904167445A5076214794 @default.
• W2904167445 hasAuthorship W2904167445A5082840545 @default.
• W2904167445 hasBestOaLocation W29041674451 @default.
• W2904167445 hasConcept C121608353 @default.
• W2904167445 hasConcept C126322002 @default.
• W2904167445 hasConcept C126838900 @default.
• W2904167445 hasConcept C142724271 @default.
• W2904167445 hasConcept C143409427 @default.
• W2904167445 hasConcept C2777111374 @default.
• W2904167445 hasConcept C2777843234 @default.
• W2904167445 hasConcept C2780472235 @default.
• W2904167445 hasConcept C2781156865 @default.
• W2904167445 hasConcept C2989005 @default.
• W2904167445 hasConcept C530470458 @default.
• W2904167445 hasConcept C544855455 @default.
• W2904167445 hasConcept C71924100 @default.
• W2904167445 hasConceptScore W2904167445C121608353 @default.
• W2904167445 hasConceptScore W2904167445C126322002 @default.
• W2904167445 hasConceptScore W2904167445C126838900 @default.
• W2904167445 hasConceptScore W2904167445C142724271 @default.
• W2904167445 hasConceptScore W2904167445C143409427 @default.
• W2904167445 hasConceptScore W2904167445C2777111374 @default.
• W2904167445 hasConceptScore W2904167445C2777843234 @default.
• W2904167445 hasConceptScore W2904167445C2780472235 @default.
• W2904167445 hasConceptScore W2904167445C2781156865 @default.
• W2904167445 hasConceptScore W2904167445C2989005 @default.
• W2904167445 hasConceptScore W2904167445C530470458 @default.
• W2904167445 hasConceptScore W2904167445C544855455 @default.
• W2904167445 hasConceptScore W2904167445C71924100 @default.
• W2904167445 hasIssue "4" @default.
• W2904167445 hasLocation W29041674451 @default.
• W2904167445 hasLocation W29041674452 @default.
• W2904167445 hasLocation W29041674453 @default.
• W2904167445 hasLocation W29041674454 @default.
• W2904167445 hasLocation W29041674455 @default.
• W2904167445 hasOpenAccess W2904167445 @default.
• W2904167445 hasPrimaryLocation W29041674451 @default.

• next